ELOA
Elongin-A
Also known as: ELOA1_HUMAN, SIII, TCEB3, TCEB3A
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q14241
- Gene
- ELOA
- Ensembl
- ENSG00000011007
- Chromosome
- 1
- Canonical length
- 772 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nuclear speckles,Cytosol
OverviewNCBI Gene
This gene encodes the protein elongin A, which is a subunit of the transcription factor B (SIII) complex. The SIII complex is composed of elongins A/A2, B and C. It activates elongation by RNA polymerase II by suppressing transient pausing of the polymerase at many sites within transcription units. Elongin A functions as the transcriptionally active component of the SIII complex, whereas elongins B and C are regulatory subunits. Elongin A2 is specifically expressed in the testis, and capable of forming a stable complex with elongins B and C. The von Hippel-Lindau tumor suppressor protein binds to elongins B and C, and thereby inhibits transcription elongation. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
772 residues, UniProt reviewed canonical sequence.
>Q14241|ELOA
1 MAAESALQVV EKLQARLAAN PDPKKLLKYL KKLSTLPITV DILAETGVGK TVNSLRKHEH
61 VGSFARDLVA QWKKLVPVER NAEPDEQDFE KSNSRKRPRD ALQKEEEMEG DYQETWKATG
121 SRSYSPDHRQ KKHRKLSELE RPHKVSHGHE RRDERKRCHR MSPTYSSDPE SSDYGHVQSP
181 PSCTSPHQMY VDHYRSLEED QEPIVSHQKP GKGHSNAFQD RLGASQERHL GEPHGKGVVS
241 QNKEHKSSHK DKRPVDAKSD EKASVVSREK SHKALSKEEN RRPPSGDNAR EKPPSSGVKK
301 EKDREGSSLK KKCLPPSEAA SDNHLKKPKH RDPEKAKLDK SKQGLDSFDT GKGAGDLLPK
361 VKEKGSNNLK TPEGKVKTNL DRKSLGSLPK VEETDMEDEF EQPTMSFESY LSYDQPRKKK
421 KKIVKTSATA LGDKGLKKND SKSTGKNLDS VQKLPKVNKT KSEKPAGADL AKLRKVPDVL
481 PVLPDLPLPA IQANYRPLPS LELISSFQPK RKAFSSPQEE EEAGFTGRRM NSKMQVYSGS
541 KCAYLPKMMT LHQQCIRVLK NNIDSIFEVG GVPYSVLEPV LERCTPDQLY RIEEYNHVLI
601 EETDQLWKVH CHRDFKEERP EEYESWREMY LRLQDAREQR LRVLTKNIQF AHANKPKGRQ
661 AKMAFVNSVA KPPRDVRRRQ EKFGTGGAAV PEKIKIKPAP YPMGSSHASA SSISFNPSPE
721 EPAYDGPSTS SAHLAPVVSS TVSYDPRKPT VKKIAPMMAK TIKAFKNRFS RRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ELOA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.62
- Highest tissue expression
- 34 nTPM
Expression across tissuesHPA
Tissue
- pancreas: 34 nTPM
- skeletal muscle: 27 nTPM
- liver: 25 nTPM
- parathyroid gland: 23 nTPM
- tongue: 22 nTPM
- lung: 20 nTPM
Single-cell type
- parietal cells: 88 nCPM
- alveolar cells type 2: 83 nCPM
- gastric chief cells: 78 nCPM
- esophageal suprabasal cells: 65 nCPM
- pancreatic acinar cells: 62 nCPM
- suprabasal keratinocytes: 59 nCPM
Immune cell
- basophil: 20 nTPM
- memory B-cell: 16 nTPM
- intermediate monocyte: 16 nTPM
- classical monocyte: 16 nTPM
- non-classical monocyte: 15 nTPM
- myeloid DC: 14 nTPM
Brain region
- cerebellum: 19 nTPM
- medulla oblongata: 19 nTPM
- white matter: 18 nTPM
- thalamus: 18 nTPM
- midbrain: 17 nTPM
- choroid plexus: 17 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.12
- gnomAD pLI
- 1
- DepMap mean gene effect
- -0.17
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- regulation of transcription by RNA polymerase II
- transcription elongation by RNA polymerase II
- transcription initiation at RNA polymerase II promoter
Cellular components
Protein domainsUniProt · Pfam · InterPro
- F-box domain
- Transcription elongation factor, TFIIS/CRSP70, N-terminal, sub-type
- RNA polymerase II transcription factor SIII, subunit A
- Transcription factor IIS, N-terminal
- TFIIS/LEDGF domain superfamily
- Elongin-A domain-containing protein
- RNA polymerase II transcription factor SIII (Elongin) subunit A
- TFIIS helical bundle-like domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ELOA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ELOA as an antibody target. Whether an autoantibody or antibody against ELOA could matter depends on whether native ELOA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ELOA is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ELOA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...